ES
UPB

Enavate Sciences’s Upstream Bio Inc UPB Stock Holding History

Enavate Sciences’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Hold
2,459,703
– – 4.93% 6
2026
Q1 		$22.1M Hold
2,459,703
– – 6.3% 6
2025
Q4 		$66.8M Hold
2,459,703
– – 13.18% 4
2025
Q3 		$46.3M Hold
2,459,703
– – 14.13% 4
2025
Q2 		$27M Hold
2,459,703
– – 15.3% 4
2025
Q1 		$15.1M Hold
2,459,703
– – 11.34% 5
2024
Q4 		$40.4M Buy
+2,459,703
New +$54.9M 29.04% 1

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Enavate Sciences's UPB Position: Q2 2026 in Review

Enavate Sciences held its Upstream Bio Inc (UPB) position steady in Q2 2026 at 2,459,703 shares worth $17M. The position accounts for 4.93% of the portfolio, ranked #6.

Enavate Sciences first reported a position in UPB in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.8M in Q4 2025. 149 funds tracked by Wall St. Rank hold UPB as of Q2 2026.

  • Enavate Sciences held 2,459,703 shares of Upstream Bio Inc worth $17M as of Q2 2026.
  • Enavate Sciences left its Upstream Bio Inc share count unchanged in Q2 2026.
  • Upstream Bio Inc made up 4.93% of Enavate Sciences's portfolio in Q2 2026, its #6 holding.
  • Enavate Sciences first reported a position in Upstream Bio Inc in Q4 2024 and has held it in 7 quarters since.
  • Enavate Sciences's Upstream Bio Inc position peaked at $66.8M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q2 2026.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.